GEN Exclusives

More »

GEN News Highlights

More »
Apr 2, 2007

Roche Strengthens Antibody Research with $56.5M Acquisition

  • Roche paid $56.5 million for antibody technology company Therapeutic Human Polyclonals (THP). The company reports that the acquisition strengthens its expertise in therapeutic antibody research.

    Roche plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research organization in Penzberg, Germany.

    A California-based company with a subsidiary in Germany, THP is focused on research in human antibody technologies. The company has developed a transgenic mammalian platform to create human antibodies. Roche reports that this technology will enable it to generate monoclonal and polyclonal antibody therapeutics with enhanced efficacy.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?